Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: CYTK cytokinetics.com
Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of expertise in muscle biology. Its commercial product, MYQORZO (aficamten), is a cardiac myosin inhibitor approved in the U.S., China, Europe, and the UK for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. Following positive Phase 3 results from ACACIA-HCM, the company is pursuing a label expansion into non-obstructive HCM with a supplemental NDA planned for Q4 2026. Cytokinetics' pipeline includes omecamtiv mecarbil, an investigational cardiac myosin activator in Phase 3 for heart failure with severely reduced ejection fraction (COMET-HF trial); ulacamten, an investigational cardiac myosin inhibitor in Phase 2 for heart failure with preserved ejection fraction (AMBER-HFpEF trial); and CK-4015089 (CK-089), a fast skeletal muscle troponin activator in Phase 1. The company has collaboration agreements with Sanofi (aficamten in China, Hong Kong, and Taiwan) and Bayer (aficamten in Japan), and has financing arrangements with entities affiliated with Royalty Pharma. Cytokinetics trades on the Nasdaq under the ticker CYTK. Updated
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the…
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs,…
Tuesday's top analyst upgrades and downgrades included Array Technologies, CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Intercontinental Exchange, Medical Properties Trust, Paramount Global and Tesla.
Wednesday's top analyst upgrades and downgrades included Apple, Boston Scientific, Caterpillar, Ciena, Costco Wholesale, Generac, Hasbro, Rivian Automotive, Steel Dynamics, Tapestry, Trade Desk and Walmart.
Tuesday's top analyst upgrades and downgrades included Bank of New York Mellon, Cloudflare, Consolidated Edison, Ford, IBM, Incyte, Simon Properties and Skechers.
Here's the Thursday afternoon edition of analysts' upgrades, downgrades and price target changes on several popular stocks.
Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of expertise in muscle biology.
The Wall Street consensus 12-month price target for CYTK is $109.95. CYTK price prediction →
